Cargando…
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
BACKGROUND: Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab (Herceptin), has become a pivotal obstacle for targeted therapy of HER2-positive breast cancers. The activation of alternative growth factor receptors, in particular, the insulin-like growth factor 1 receptor (IGF1R), re...
Autores principales: | Ye, Xing-Ming, Zhu, Hua-Yu, Bai, Wen-Dong, Wang, Ting, Wang, Lei, Chen, Ying, Yang, An-Gang, Jia, Lin-Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974046/ https://www.ncbi.nlm.nih.gov/pubmed/24571711 http://dx.doi.org/10.1186/1471-2407-14-134 |
Ejemplares similares
-
MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
por: Ye, Xingming, et al.
Publicado: (2014) -
Expression and prognostic significance of miR-375 and miR-221 in liver cancer
por: Xie, Dafei, et al.
Publicado: (2017) -
miR-375 Suppresses IGF1R Expression and Contributes to Inhibition of Cell Progression in Laryngeal Squamous Cell Carcinoma
por: Luo, Jie, et al.
Publicado: (2014) -
Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma
por: Xue, Hui-Ying, et al.
Publicado: (2016) -
Exosome-Encapsulated miR-31, miR-192, and miR-375 Serve as Clinical Biomarkers of Gastric Cancer
por: He, Jing, et al.
Publicado: (2023)